Fuse Science Announces Major Advancements in Delivery of APIs

Fuse Science, Inc. recently announced their Round II Research results have shown their proprietary delivery technology has successfully delivered therapeutic doses of varying-size compounds directly through the epidermis.

During the company’s Round I Research conducted in 2012, caffeine was delivered effectively through the epidermis. This initial study provided four basic principles surrounding Fuse Science’s proprietary technology: speed, variability, duration, and functionality.

The Round II Research results released May 31, 2013, expanded the prior proof-of- concepts by showing Fuse’s proprietary delivery technology successfully delivering numerous APIs of varying size, rigidity, and lipophilicity, whether it is fat or water soluble, directly through the epidermis. Nine Fuse Science formulations were tested in an ex vivo penetration study through human epidermis. Eight compounds were tested with the proprietary encapsulation technology, and one of them was tested with a second proprietary encapsulation formulation. Fuse Science’s proprietary technology delivered Insulin, Paclitaxel, Estradiol, Nicotinic Acid, Folic Acid, Polyethylene Glycol (PEG), Vitamin E Acetate, and caffeine with 100% success rate.

“We are very excited with the recent findings that are providing clear evidence that our delivery technology could be a significant advancement in how medicines, vitamins, and nutritional compounds are delivered and absorbed into the human body,” said Jeanne Hebert, Vice President of Market and Clinical Research of Fuse Science.

Insulin, one of the compounds previously analyzed, is a reliable proof-of-principle for the technology. Because it is such a large molecule, and a protein, it has been traditionally very difficult to deliver through the skin unless it was given via an injection. During this study, it passed through even at low concentrations in the company’s proprietary formulation.

In addition, two other large-market drugs, Estradiol, used to treat the symptoms of menopause, and Paclitaxel, a prescription cancer drug, were tested. It is Fuse’s hypothesis, based on the success of their research, that they will be successful in the delivery of therapeutic doses of each, within their matrix, in a simple roll-on application.
The primary benefits that may develop from these studies are:

• Enhanced delivery option for complex APIs
• Improved bioavailability or enhanced absorption in the body
• Stronger product efficacy
• Enhanced ease of use (a simple roll-on application)
• Expansion of therapeutic options for acute, rapid onset conditions

Data from these preliminary research studies show that with little requirement for optimization, the technology can provide for the transdermal delivery of drugs at clinically relevant doses for the treatment of a wide variety of ailments and diseases. Most compounds showed improvement of delivery over each time-point during the course of the study. The lack of plateaus would suggest that delivery improves with time and can be sustained for periods much greater than 24 hours.

This latest research is particularly relevant to the active licensing and M&A efforts of the company. The full Round II Research report can be found by visiting the Clinical Research section of the Fuse Science Investor Relations page at http://ir.stockpr.com/fusescience/clinical-research.

Fuse Science, Inc. is an innovative consumer products and delivery technology company based in Miami Lakes, FL. Fuse Science holds the rights to new, patent-pending technologies poised to redefine how consumers receive energy, medicines, vitamins, and minerals. The company maintains the rights to sublingual and transdermal delivery systems for bioactive agents that can now, for the first time, effectively encapsulate and charge many varying molecules in order to produce complete product formulations that can bypass the gastrointestinal tract and enter the blood stream directly – all in a concentrated DROP form that is simply applied under the tongue. For more information, visit www.fusescience.com or www.poweredbyfuse.com.